Page 25 - Syncona Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...

06 May 2021 Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, notes that its portfolio company, Autolus Therapeutics Plc (NASDAQ: AUTL) (Autolus), announced its operational and financial results for the first quarter ended March 31, 2021. The announcement can be accessed on Autolus' investor website at  https://www.autolus.com/investor-relations  and full text of the announcement from Autolus is contained below. Autolus management will host a conference call today, at 8:...

LONDON--(BUSINESS WIRE)--Mar 1, 2021--

IN BRIEF: Syncona's Gyroscope Reports Positive Results From GT005 Test Fri, 12th Feb 2021 16:24 Syncona Ltd - London-based life sciences investor - Portfolio firm Gyroscope Therapeutics Ltd announces positive interim safety, protein expression and biomarker data from the open-label Phase I/II Focus clinical trial of its gene therapy GT005, for patients with geographic atrophy secondary to age-related macular degeneration. Data showed that GT005 was well tolerated in patients. "We are highly encouraged by the early data from Gyroscope's Phase I/II Focus trial, which suggests that the administr...

11 February 2021 · Further commitment of £25.3 million in a £61.0 million expanded Series A; taking Syncona's total commitment to Quell to £59.3 million · First company globally targeting liver transplantation with engineered T regulatory cell therapy; set for clinical entry in the first half of 2022   · Research programmes initiated in Type 1 Diabetes ("T1D") and Amyotrophic Lateral Sclerosis ("ALS") Syncona Ltd ("Syncona") announces a £25.3 million new commitment in a £61.0 million expanded Series A financing for Quell Therap...